繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药推荐 >> KADCYLA(ADO-TRASTUZUMAB EMTANSINE.T-DM1,Powder for Infusion)

KADCYLA(ADO-TRASTUZUMAB EMTANSINE.T-DM1,Powder for Infusion)

2014-12-13 02:30:12  作者:新特药房  来源:互联网  浏览次数:561  文字大小:【】【】【
简介: 2013年11月21日,罗氏(Roche)抗体偶联药物Kadcyla(trastuzumab emtansine,T-DM1)获欧盟委员会(EC)批准,用于既往接受过赫赛汀(Herceptin,通用名:trastuzumab,曲妥珠单抗)及一种紫衫类药物 ...

2013年11月21日,罗氏(Roche)抗体偶联药物Kadcyla(trastuzumab emtansine,T-DM1)获欧盟委员会(EC)批准,用于既往接受过赫赛汀(Herceptin,通用名:trastuzumab,曲妥珠单抗)及一种紫衫类药物(taxane)治疗的、不能手术切除的局部晚期或转移性HER2阳性乳腺癌患者的治疗。
Kadcyla的获批,是基于国际性III期EMILIA研究的临床数据,该试验在既往接受过赫赛汀(Herceptin,通用名:trastuzumab,曲妥珠单抗)和一种紫杉类药物(taxane)治疗的HER2阳性转移性乳腺癌患者中开展,将Kadcyla与标准疗法进行了对比。研究数据表明,与标准疗法相比,Kadcyla显着改善了总生存期(OS,30.9个月 vs 25.1个月)和无进展生存期(PFS,9.6个月 vs 6.4个月),同时更少的患者经历严重不良事件。
此前,Kadcyla已分别于今年2月和9月获FDA和日本劳动卫生福利部(MHLW)批准,用于不能手术或复发性HER2阳性乳腺癌的治疗。
Kadcyla是首个获批用于HER2阳性转移性乳腺癌治疗的抗体偶联药物(ADC)。
目前,转移性乳腺癌(mBC)还没有可治愈的药物,因此,治疗的目的是帮助患者尽可能地生存的更久。HER2阳性mBR的治疗包括靶向药物和化疗方案。一些与标准化疗相关的副作用,会显着影响患者的生活质量,有时甚至有必要换药或停药。
关于Kadcyla:
Kadcyla是一种HER2靶向性疗法,是一种由罗氏曲妥珠单抗与ImmunoGen公司DM1细胞毒制剂相偶联的药物,具有2种抗癌属性:曲妥珠单抗的HER2抑制和DM1的细胞毒性。曲妥珠单抗和DM1之间采用一种稳定的连接子(linkers)偶联,将DM1递送至HER2阳性乳腺癌细胞。罗氏拥有Kadcyla的全球开发和商业化权利。
目前,罗氏正在开展数个研究,评价Kadcyla用于潜在额外用途的潜力,包括用于HER2阳性转移性乳腺癌的一线治疗,用于早期HER2阳性乳腺癌、晚期HER2阳性胃癌的治疗。


Kadcyla 100 mg & 160 mg Powder for Concentrate for Solution for Infusion
1. Name of the medicinal product
Kadcyla 100 mg powder for concentrate for solution for infusion.
Kadcyla 160 mg powder for concentrate for solution for infusion.
2. Qualitative and quantitative composition
100 mg single-use vial containing powder for concentrate for infusion solution delivers 5 mL of 20 mg/mL of trastuzumab emtansine after reconstitution (see section 6.6).
160mg single-use vial containing powder for concentrate for infusion solution delivers 8 mL of 20 mg/mL of trastuzumab emtansine after reconstitution (see section 6.6).
Trastuzumab emtansine is an antibody-drug conjugate that contains trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture, covalently linked to DM1, a microtubule inhibitor, via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Powder for concentrate for solution for infusion.
White to off-white lyophilised powder.
4. Clinical particulars
4.1 Therapeutic indications
Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
• Received prior therapy for locally advanced or metastatic disease, or
• Developed disease recurrence during or within six months of completing adjuvant therapy.
4.2 Posology and method of administration
Kadcyla should only be prescribed by a physician and administered under the supervision of a healthcare professional who is experienced in the treatment of cancer patients.
Patients treated with trastuzumab emtansine should have HER2 positive tumour status, defined as a score of 3 + by immunohistochemistry (IHC) or a ratio of ≥ 2.0 by in situ hybridization (ISH) assessed by a CE-marked In Vitro Diagnostic (IVD) medical device. If a CE-marked IVD is not available, the HER2-status should be assessed by an alternate validated test.
In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).
Posology
The recommended dose of trastuzumab emtansine is 3.6 mg/kg bodyweight administered as an intravenous infusion every 3 weeks (21-day cycle). Patients should be treated until disease progression or unacceptable toxicity.
The initial dose should be administered as a 90 minute intravenous infusion. Patients should be observed during the infusion and for at least 90 minutes following the initial infusion for fever, chills, or other infusion-related reactions. The infusion site should be closely monitored for possible subcutaneous infiltration during administration (see section 4.8).
If the prior infusion was well tolerated, subsequent doses of trastuzumab emtansine may be administered as 30 minute infusions. Patients should be observed during the infusion and for at least 30 minutes after infusion.
The infusion rate of trastuzumab emtansine should be slowed or interrupted if the patient develops infusion-related symptoms (see sections 4.4 and 4.8). Trastuzumab emtansine should be discontinued in case of life-threatening infusion reactions.
Medicinal products to treat allergic/anaphylactic infusion reactions, as well as emergency equipment should be available for immediate use (see section 4.4).
Delayed or missed dose
If a planned dose is missed, it should be administered as soon as possible; do not wait until the next planned cycle. The schedule of administration should be adjusted to maintain a 3-week interval between doses. The next dose should be administered in accordance with the dosing recommendations (see section 4.2, Posology).
Dose modification
Management of symptomatic adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of Kadcyla as per guidelines provided in text and Tables 1 to 5.
Kadcyla dose should not be re-escalated after a dose reduction is made.
Table 1 Dose reduction schedule

Dose reduction schedule

(Starting dose is 3.6 mg/kg)

Dose to be administered

First dose reduction

3 mg/kg

Second dose reduction

2.4 mg/kg

Requirement for further dose reduction

Discontinue treatment

Table 2 Dose modification guidelines for increased transaminases (AST/ALT)

Grade 2

(> 2.5 to ≤ 5 × the ULN)

Grade 3

(> 5 to ≤ 20 × the ULN)

Grade 4

(> 20 × the ULN)

No dose modification is required.

Do not administer trastuzumab emtansine until AST/ALT recovers to Grade ≤ 2 (>2.5 to ≤5 x ULN), and then dose reduce (see table 1).

Discontinue trastuzumab emtansine

ALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal.
Table 3 Dose modification guidelines for hyperbilirubinemia

Grade 2

(> 1.5 to ≤ 3 × the ULN)

Grade 3

(> 3 to ≤ 10 × the ULN)

Grade 4

(> 10 × the ULN)

Do not administer trastuzumab emtansine until total bilirubin recovers to Grade ≤ 1 (>ULN to 1.5x ULN). No dose modification is required.

Do not administer trastuzumab emtansine until total bilirubin recovers to Grade ≤ 1 (>ULN to 1.5x ULN), and then dose reduce (see table 1).

Discontinue trastuzumab emtansine.

ULN = upper limit of normal.
Table 4 Dose modification guidelines for thrombocytopenia

Grade 3

(Platelets: 25,000 to < 50,000/mm3)

Grade 4

(Platelets: < 25,000/mm3)

Do not administer trastuzumab emtansine until platelet count recovers to ≤ Grade 1 (i.e. platelets ≥ 75,000/mm3). No dose modification is required.

Do not administer trastuzumab emtansine until platelet count recovers to ≤ Grade 1 (i.e. platelets ≥ 75,000/mm3), and then dose reduce (see table 1).

Table 5 Dose modifications for left ventricular dysfunction

LVEF < 40%

LVEF > 45%

LVEF 40% to ≤ 45% and decrease is < 10% points from baseline

LVEF 40% to ≤ 45% and decrease is ≥ 10% points from baseline

Symptomatic CHF

Do not administer trastuzumab emtansine.

Repeat LVEF assessment within 3 weeks. If LVEF < 40% is confirmed, discontinue trastuzumab emtansine.

Continue treatment with trastuzumab emtansine.

Continue treatment with trastuzumab emtansine.

Repeat LVEF assessment within 3 weeks.

Do not administer trastuzumab emtansine.

Repeat LVEF assessment within 3 weeks. If the LVEF has not recovered to within 10% points from baseline, discontinue trastuzumab emtansine.

Discontinue trastuzumab emtansine

LVEF = Left ventricular ejection fraction
Peripheral neuropathy
Trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to ≤ Grade 2. At retreatment a dose reduction may be considered according to the dose reduction schedule (see Table 1).
Elderly patients
No dose adjustment is required in patients aged ≥ 65 years. There are insufficient data to establish the safety and efficacy in patients ≥ 75 years due to limited data in this subgroup. Population pharmacokinetic analysis indicates that age does not have a clinically meaningful effect on the pharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).
Patients with renal impairment
No adjustment to the starting dose is needed in patients with mild or moderate renal impairment (see section 5.2). The potential need for dose adjustment in patients with severe renal impairment cannot be determined due to insufficient data and therefore patients with severe renal impairment should be monitored carefully.
Patients with hepatic impairment
The safety and efficacy have not been studied in patients with hepatic impairment. No specific dose recommendations can be made (see section 4.4).
Paediatric population
The safety and efficacy in children and adolescents below 18 years of age have not been established as there is no relevant use in the paediatric population in the indication of metastatic breast cancer (MBC).
Method of administration
Trastuzumab emtansine must be reconstituted and diluted by a healthcare professional and administered as an intravenous infusion. It must not be administered as an intravenous push or bolus.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
In order to improve traceability of biological medicinal products, the tradename of the administered product should be clearly recorded (or stated) in the patient file.
In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).
Pulmonary toxicity
Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute respiratory distress syndrome or a fatal outcome, have been reported in clinical studies with trastuzumab emtansine (see section 4.8). Signs and symptoms include dyspnoea, cough, fatigue, and pulmonary infiltrates.
It is recommended that treatment with trastuzumab emtansine be permanently discontinued in patients who are diagnosed with ILD or pneumonitis.
Patients with dyspnoea at rest due to complications of advanced malignancy and co-morbidities may be at increased risk of pulmonary events.
Hepatotoxicity
Hepatotoxicity, predominantly in the form of asymptomatic increases in the concentrations of serum transaminases (Grade 1-4 transaminitis), has been observed during treatment with trastuzumab emtansine in clinical studies (see section 4.8). Transaminase elevations were generally transient with peak elevation at day 8 after administration of therapy and subsequent recovery to Grade 1 or less prior to the next cycle. A cumulative effect on transaminases has also been observed (the proportion of patients with Grade 1-2 ALT/AST abnormalities increases with successive cycles).
Patients with elevated transaminases improved to Grade 1 or normal within 30 days of the last dose of trastuzumab emtansine in the majority of the cases (see section 4.8).
Serious hepatobiliary disorders, including nodular regenerative hyperplasia (NRH) of the liver and some with a fatal outcome due to drug-induced liver injury have been observed in patients treated with trastuzumab emtansine. Observed cases may have been confounded by comorbidities and/or concomitant medicinal products with known hepatotoxic potential.
Liver function should be monitored prior to initiation of treatment and each dose. Patients with baseline elevation of ALT (e.g. due to liver metastases) may be predisposed to liver injury with a higher risk of a Grade 3-5 hepatic event or liver function test increase. Dose reductions or discontinuation for increased serum transaminases and total bilirubin are specified in section 4.2.
Cases of nodular regenerative hyperplasia (NRH) of the liver have been identified from liver biopsies in patients treated with trastuzumab emtansine. NRH is a rare liver condition characterised by widespread benign transformation of hepatic parenchyma into small regenerative nodules; NRH may lead to non-cirrhotic portal hypertension. Diagnosis of NRH can be confirmed only by histopathology. NRH should be considered in all patients with clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on the computed tomography (CT) scan of the liver but with normal transaminases and no other manifestations of cirrhosis. Upon diagnosis of NRH, trastuzumab emtansine treatment must be permanently discontinued.
Trastuzumab emtansine has not been studied in patients with serum transaminases > 2.5 × ULN or total bilirubin > 1.5 × ULN prior to initiation of treatment. Treatment in patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN should be permanently discontinued.
Left ventricular dysfunction
Patients treated with trastuzumab emtansine are at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) < 40% has been observed in patients treated with trastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF) is a potential risk (see section 4.8). General risk factors for a cardiac event and those identified in adjuvant breast cancer studies with trastuzumab therapy include advancing age (> 50 years), low baseline LVEF values (< 55%), low LVEF levels prior to or following the use of paclitaxel in the adjuvant setting, prior or concomitant use of antihypertensive medicinal products, previous therapy with an anthracycline and high BMI (> 25 kg/m2).
Standard cardiac function testing (echocardiogram or multigated acquisition (MUGA) scanning) should be performed prior to initiation and at regular intervals (e.g. every three months) during treatment. In clinical studies, patients had a LVEF ≥ 50% at baseline. Patients with a history of congestive heart failure (CHF), serious cardiac arrhythmia requiring treatment, history of myocardial infarction or unstable angina within 6 months of randomization, or current dyspnoea at rest due to advanced malignancy were excluded from clinical studies. The dose should be delayed or treatment discontinued as necessary in cases of left ventricular dysfunction (see section 4.2).
Infusion-related reactions
Trastuzumab emtansine treatment has not been studied in patients who had trastuzumab permanently discontinued due to infusion-related reactions (IRR); treatment is not recommended for these patients. Patients should be observed closely for infusion-related reactions, especially during the first infusion.
Infusion-related reactions (due to cytokine release), characterized by one or more of the following symptoms -have been reported: flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia. In general, these symptoms were not severe (see section 4.8). In most patients, these reactions resolved over the course of several hours to a day after the infusion was terminated. Treatment should be interrupted in patients with a severe IRR until signs and symptoms resolve. Consideration for re-treatment should be based on clinical assessment of the severity of the reaction. Treatment must be permanently discontinued in the event of a life threatening infusion-related reaction (see section 4.2).
Hypersensitivity reactions
Trastuzumab emtansine treatment has not been studied in patients who had trastuzumab permanently discontinued due to hypersensitivity; treatment with trastuzumab emtansine is not recommended for these patients.
Patients should be observed closely for hypersensitivity/allergic reactions, which may have the same clinical presentation as an IRR. Serious, anaphylactic reactions have been observed in clinical studies with trastuzumab emtansine. Medicinal products to treat such reactions, as well as emergency equipment, should be available for immediate use. In the event of a true hypersensitivity reaction (in which severity of reaction increases with subsequent infusions), trastuzumab emtansine treatment must be permanently discontinued.
Thrombocytopenia
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (see section 4.8). In clinical studies, the incidence and severity of thrombocytopenia were higher in Asian patients (see section 4.8).
Cases of bleeding events with a fatal outcome have been observed. Severe cases of haemorrhagic events, including central nervous system haemorrhage, have been reported in clinical studies; these events were independent of ethnicity. In some of the observed cases the patients were also receiving anti-coagulation therapy.
It is recommended that platelet counts are monitored prior to each trastuzumab emtansine dose. Patients with thrombocytopenia (≤ 100,000/mm3) and patients on anti-coagulant treatment (e.g. warfarin, heparin, low molecular weight heparins) should be monitored closely while on trastuzumab emtansine treatment. Trastuzumab emtansine has not been studied in patients with platelet counts ≤ 100,000/mm3 prior to initiation of treatment. In the event of decreased platelet count to Grade 3 or greater (< 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to Grade 1 (≥ 75,000/mm3) (see section 4.2).
Neurotoxicity
Peripheral neuropathy, mainly Grade 1 and predominantly sensory, has been reported in clinical studies with trastuzumab emtansine. Patients with Grade ≥ 3 peripheral neuropathy at baseline were excluded from clinical studies. Treatment with trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until symptoms resolve or improve to ≤ Grade 2. Patients should be clinically monitored on an ongoing basis for signs/symptoms of neurotoxicity.
Sodium content in excipients
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium- free'.
4.5 Interaction with other medicinal products and other forms of interaction
No formal interaction studies have been performed.
In vitro metabolism studies in human liver microsomes suggest that DM1, a component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and, to a lesser extent, by CYP3A5. Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) with trastuzumab emtansine should be avoided due to the potential for an increase in DM1 exposure and toxicity. Consider an alternate medicinal product with no or minimal potential to inhibit CYP3A4. If concomitant use of strong CYP3A4 inhibitors is unavoidable, consider delaying trastuzumab emtansine treatment until the strong CYP3A4 inhibitors have cleared from the circulation (approximately 3 elimination half-lives of the inhibitors) when possible. If a strong CYP3A4 inhibitor is coadministered and trastuzumab emtansine treatment cannot be delayed, patients should be closely monitored for adverse reactions.
4.6 Fertility, pregnancy and lactation
Contraception in males and females
Women of childbearing potential should use effective contraception while receiving trastuzumab emtansine and for 7 months following the last dose of trastuzumab emtansine. Male patients or their female partners should also use effective contraception.
Pregnancy
There are no data from the use of trastuzumab emtansine in pregnant women. Trastuzumab, a component of trastuzumab emtansine, can cause foetal harm or death when administered to a pregnant woman. In the post-marketing setting, cases of oligohydramnios, some associated with fatal pulmonary hypoplasia, have been reported in pregnant women receiving trastuzumab. Animal studies of maytansine, a closely related chemical entity of the same maytansinoid class as DM1, suggest that DM1, the microtubule inhibiting cytotoxic component of trastuzumab emtansine, is expected to be teratogenic and potentially embryotoxic (see section 5.3).
Administration of trastuzumab emtansine to pregnant women is not recommended and women should be informed of the possibility of harm to the foetus before they become pregnant. Women who become pregnant must immediately contact their doctor. If a pregnant woman is treated with trastuzumab emtansine, close monitoring by a multidisciplinary team is recommended.
Breast-feeding
It is not known whether trastuzumab emtansine is excreted in human milk. Since many medicinal products are excreted in human milk and because of the potential for serious adverse reactions in breast-feeding infants, women should discontinue breast-feeding prior to initiating treatment with trastuzumab emtansine. Women may begin breast-feeding 7 months after concluding treatment.
Fertility
No reproductive and developmental toxicology studies have been conducted with trastuzumab emtansine.
4.7 Effects on ability to drive and use machines
Trastuzumab emtansine has no or negligible influence on the ability to drive and use machines.
The significance of reported adverse reactions such as fatigue, headache, dizziness and blurred vision on the ability to drive or use machines is unknown. Patients experiencing infusion-related reactions should be advised not to drive and use machines until symptoms abate.
4.8 Undesirable effects
Summary of the safety profile
The safety of trastuzumab emtansine has been evaluated in 884 breast cancer patients in clinical studies. In this patient population:
• the most common serious ADRs were pyrexia, thrombocytopenia, vomiting, abdominal pain, nausea, constipation, diarrhoea, dyspnoea and pneumonitis.
• the most common adverse drug reactions (ADRs) (≥25%) with trastuzumab emtansine were haemorrhage (including epistaxis), increased transaminases, fatigue, musculoskeletal pain, and headache. The majority of ADRs reported were of Grade 1 or 2 severity.
• the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 3 or 4 ADRs (> 2%) were thrombocytopenia, fatigue, increased transaminases, anaemia, hypokalaemia, musculoskeletal pain and neutropenia.
Tabulated list of adverse reactions
The ADRs in 884 patients treated with trastuzumab emtansine are presented in Table 6. The ADRs are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and SOC, adverse reactions are presented in order of decreasing seriousness. ADRs were reported using NCI-CTCAE for assessment of toxicity.
Table 6 Tabulated list of ADRs in patients treated with trastuzumab emtansine

System Organ Class

Very Common

Common

Uncommon

Infections and infestations

Urinary tract infection

   

Blood and lymphatic system disorders

Thrombocytopenia, Anaemia

Neutropenia, Leucopoenia

 

Immune system disorders

 

Drug hypersensitivity

 

Metabolism and nutrition disorders

Hypokalaemia

   

Psychiatric disorders

Insomnia

   

Nervous system disorders

Neuropathy peripheral, Headache, Dizziness

Dysgeusia, Memory impairment

 

Eye disorders

 

Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased

 

Cardiac disorders

 

Left ventricular dysfunction

 

Vascular disorders

Haemorrhage

Hypertension

 

Respiratory, thoracic and mediastinal disorders

Epistaxis, Cough, Dyspnoea

 

Pneumonitis (ILD)

Gastrointestinal disorders

Stomatitis, Diarrhoea, Vomiting, Nausea, Constipation, Dry mouth, Abdominal pain

Dyspepsia, Gingival bleeding

 

Hepatobiliary disorders

   

Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia, Portal hypertension

Skin and subcutaneous tissue disorders

Rash

Pruritus, Alopecia, Nail disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria

 

Musculoskeletal and connective tissue disorders

Musculoskeletal pain, Arthralgia, Myalgia

   

General disorders and administration site conditions

Fatigue, Pyrexia, Asthenia, Chills

Peripheral oedema

Injection site extravasation

Investigations

Transaminases increased

Blood alkaline phosphatase increased

 

Injury, poisoning and procedural complications

 

Infusion-related reactions

 
Description of selected adverse reactions
Transaminases increased (AST/ALT)
Increase in serum transaminases (Grade 1-4) has been observed during treatment with trastuzumab emtansine in clinical studies (see section 4.4). Transaminase elevations were generally transient. A cumulative effect of trastuzumab emtansine on transaminases has been observed, and generally recovered when treatment was discontinued. Increased transaminases were reported in 28% of patients in clinical studies. Grade 3 or 4 increased AST and ALT were reported in 4.1% and 2.8% of patients respectively and usually occurred in the early treatment cycles (1-6). In general, the Grade ≥ 3 hepatic events were not associated with poor clinical outcome; subsequent follow-up values tended to show improvement to ranges allowing the patient to remain on study and continue to receive study treatment at the same or reduced dose. No relationship was observed between trastuzumab emtansine exposure (AUC), trastuzumab emtansine maximum serum concentration (Cmax), total trastuzumab exposure (AUC), or Cmax of DM1 and increases in transaminase. For dose modifications in the event of increased transaminases, see sections 4.2 and 4.4.
Left ventricular dysfunction
Left ventricular dysfunction was reported in 2.0% of patients in clinical studies with trastuzumab emtansine. The majority of events were asymptomatic Grade 1 or 2 decrease in LVEF. Grade 3 or 4 events were reported in 0.3% of patients. These uncommon Grade 3 or 4 events usually occurred in the early treatment cycles (1-2). Additional LVEF monitoring is recommended for patients with LVEF ≤ 45% (See Table 5 in section 4.2 for specific dose modifications).
Infusion-related reactions
Infusion-related reactions are characterised by one or more of the following symptoms: flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm and tachycardia. Infusion-related reactions were reported in 4.5% of patients in clinical studies with trastuzumab emtansine, with one Grade 3 and no Grade 4 events reported. Infusion-related reactions resolved over the course of several hours to a day after the infusion was terminated. No dose relationship was observed in clinical studies. For dose modifications in the event of infusion-related reactions, see sections 4.2 and 4.4.
Hypersensitivity reactions
Hypersensitivity was reported in 2.6% of patients in clinical studies with trastuzumab emtansine, with no Grade 3 or 4 events reported. Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatment. For dose modifications in the event of hypersensitivity reactions, see sections 4.2 and 4.4.
Thrombocytopenia
Thrombocytopenia or decreased platelet counts were reported in 31.4% of patients in clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (1.4%). The majority of the patients had Grade 1 or 2 events (≥ 50,000/mm3), with the nadir occurring by day 8 and generally improving to Grade 0 or 1 (≥ 75,000/mm3) by the next scheduled dose. In clinical studies, the incidence and severity of thrombocytopenia were higher in Asian patients. Independent of race, the incidence of Grade 3 or 4 events (< 50,000/mm3) was 11.3% in patients treated with trastuzumab emtansine. The incidence of severe haemorrhagic events (Grade ≥3) occurred in 1.7% of the overall trastuzumab emtansine treated patients and 1% of Asian trastuzumab emtansine treated patients. In some of the observed cases the patients were also receiving anti-coagulation therapy. Cases of bleeding events with a fatal outcome have been observed. For dose modifications for thrombocytopenia, see sections 4.2 and 4.4.
Immunogenicity
As with all therapeutic proteins, there is the potential for an immune response to trastuzumab emtansine. A total of 836 patients from six clinical studies were tested at multiple time points for anti-therapeutic antibody (ATA) responses to trastuzumab emtansine. Following dosing, 5.3% (44/836) of patients tested positive for anti-trastuzumab emtansine antibodies at one or more post-dose time points. The clinical significance of anti-trastuzumab emtansine antibodies is not yet known.
Extravasation
Reactions secondary to extravasation have been observed in clinical studies with trastuzumab emtansine. These reactions were usually mild and comprised erythema, tenderness, skin irritation, pain, or swelling at the infusion site. These reactions have been observed more frequently within 24 hours of infusion. Specific treatment for trastuzumab emtansine extravasation is unknown at this time.
Laboratory abnormalities
Table 7 displays laboratory abnormalities observed in patients treated with trastuzumab emtansine in clinical study TDM4370g/BO21977.
Table 7 Laboratory abnormalities observed in patients treated with trastuzumab emtansine in study TDM4370g/BO21977

Parameter

Trastuzumab emtansine

All Grades (%)

Grade 3 (%)

Grade 4 (%)

Hepatic

Increased bilirubin

20

< 1

0

Increased AST

98

7

< 1

Increased ALT

82

5

< 1

Haematologic

Decreased platelets

84

14

3

Decreased haemoglobin

62

4

1

Decreased neutrophils

39

4

< 1

Potassium

Decreased potassium

34

3

<1

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below).
Ireland
Pharmacovigilance Section
Health Products Regulatory Authority
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie
Mata
ADR Reporting
The Medicines Authority
Post-Licensing Directorate
203 Level 3, Rue D'Argens
GŻR-1368 Gżira
Website: www.medicinesauthority.gov.mt
e-mail: postlicensing.medicinesauthority@gov.mt
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
There is no known antidote for trastuzumab emtansine overdose. In case of overdose, the patient should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted. Cases of overdose have been reported with trastuzumab emtansine treatment, most associated with thrombocytopenia, and there was one death. In the fatal case, the patient incorrectly received trastuzumab emtansine 6 mg/kg and died approximately 3 weeks following the overdose; a causal relationship to trastuzumab emtansine was not established.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agent, other antineoplastic agents, monoclonal antibodies, ATC code: L01XC14
Mechanism of action
Kadcyla, trastuzumab emtansine, is a HER2-targeted antibody-drug conjugate which contains the humanised anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitor DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex. An average of 3.5 DM1 molecules are conjugated to each molecule of trastuzumab.
Conjugation of DM1 to trastuzumab confers selectivity of the cytotoxic agent for HER2-overexpressing tumour cells, thereby increasing intracellular delivery of DM1 directly to malignant cells. Upon binding to HER2, trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in release of DM1-containing cytotoxic catabolites (primarily lysine-MCC-DM1).
Trastuzumab emtansine has the mechanisms of action of both trastuzumab and DM1:
• Trastuzumab emtansine, like trastuzumab, binds to domain IV of the HER2 extracellular domain (ECD), as well as to Fcγ receptors and complement C1q. In addition, trastuzumab emtansine, like trastuzumab, inhibits shedding of the HER2 ECD, inhibits signalling through the phosphatidylinositol 3-kinase (PI3-K) pathway, and mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in human breast cancer cells that overexpress HER2.
• DM1, the cytotoxic component of trastuzumab emtansine, binds to tubulin. By inhibiting tubulin polymerization, both DM1 and trastuzumab emtansine cause cells to arrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic cell death. Results from in vitro cytotoxicity assays show that DM1 is 20-200 times more potent than taxanes and vinca alkaloids.
• The MCC linker is designed to limit systemic release and increase targeted delivery of DM1, as demonstrated by detection of very low levels of free DM1 in plasma.
Clinical efficacy
TDM4370g/BO21977
A Phase III, randomised, multicentre, international, open-label clinical study was conducted in patients with HER2-positive unresectable locally advanced breast cancer (LABC) or MBC who had received prior taxane and trastuzumab-based therapy, including patients who received prior therapy with trastuzumab and a taxane in the adjuvant setting and who relapsed during or within six months of completing adjuvant therapy. Only patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 were eligible. Prior to enrolment, breast tumour samples were required to be centrally confirmed for HER2-positive status defined as a score of 3 + by IHC or gene amplification by ISH. Baseline patient and tumour characteristics were well balanced between treatment groups. Patients with treated brain metastases were eligible for enrollment if they did not require therapy to control symptoms. For patients randomised to trastuzumab emtansine, the median age was 53 years, most patients were female (99.8%), the majority were Caucasian (72%), and 57% had oestrogen-receptor and/or progesterone-receptor positive disease. The study compared the safety and efficacy of trastuzumab emtansine with that of lapatinib plus capecitabine. A total of 991 patients were randomised to trastuzumab emtansine or lapatinib plus capecitabine as follows:
• Trastuzumab emtansine arm: trastuzumab emtansine 3.6 mg/kg intravenously over 30-90 minutes on Day 1 of a 21-day cycle
• Control arm (lapatinib plus capecitabine): lapatinib 1250 mg/day orally once per day of a 21-day cycle plus capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of a 21-day cycle
The co-primary efficacy endpoints of the study were progression-free survival (PFS) as assessed by an independent review committee (IRC) and overall survival (OS) (see Table 8 and Figures 1 to 2).
Time to symptom progression, as defined by a 5-point decrease in the score derived from the Trials Outcome Index-Breast (TOI-B) subscale of the Functional Assessment of Cancer Therapy-Breast Quality of Life (FACT-B QoL) questionnaire was also assessed during the clinical study. A change of 5 points in the TOI-B is considered clinically significant. Kadcyla delayed patient-reported time to symptom progression for 7.1 months compared with 4.6 months for the control arm (Hazard Ratio 0.796 (0.667, 0.951); p-value 0.0121). The data are from an open-label study and no firm conclusions can be drawn.
Table 8 Summary of efficacy from study TDM4370g/BO21977 (EMILIA)

Lapatinib + Capecitabine

n = 496

Trastuzumab emtansine

n = 495

Primary endpoints

IRC-assessed progression-free survival (PFS)

 

Number (%) of patients with event

304 (61.3%)

265 (53.5%)

Median duration of PFS (months)

6.4

9.6

Hazard ratio (stratified*)

0.650

95% CI for Hazard ratio

(0.549, 0.771)

p-value (Log-rank test, stratified*)

< 0.0001

Overall Survival (OS)**

 

Number (%) of patients who died

182 (36.7%)

149 (30.1%)

Median duration of survival (months)

25.1

30.9

Hazard ratio (stratified*)

0.682

95% CI for Hazard ratio

(0.548, 0.849)

p-value (Log-rank test*)

0.0006

Key secondary endpoints

Investigator-assessed PFS

 

Number (%) of patients with event

335 (67.5%)

287 (58.0%)

Median duration of PFS (months)

5.8

9.4

Hazard ratio (95% CI)

0.658 (0.560, 0.774)

p-value (Log-rank test*)

<0.0001

Objective response rate (ORR)

 

Patients with measurable disease

389

397

Number of patients with OR (%)

120 (30.8%)

173 (43.6%)

Difference (95% CI)

12.7% (6.0, 19.4)

p-value (Mantel-Haenszel chi-squared test*)

0.0002

Duration of objective response (months)

 

Number of patients with OR

120

173

Median 95% CI

6.5 (5.5, 7.2)

12.6 (8.4, 20.8)

OS: overall survival; PFS: progression-free survival; ORR: objective response rate; OR: objective response; IRC: independent review committee; HR: hazard ratios; CI: confidence interval
* Stratified by: world region (United States, Western Europe, other), number of prior chemotherapeutic regimens for locally advanced or metastatic disease (0-1 vs. > 1), and visceral vs. non-visceral disease.
** The interim analysis for OS was conducted when 331 events were observed. Since the efficacy boundary was crossed at this analysis, this is considered the definitive analysis.
A treatment benefit was seen in the subgroup of patients who had relapsed within 6 months of completing adjuvant treatment and had not received any prior systemic anti-cancer therapy in the metastatic setting (n=118); hazard ratios for PFS and OS were 0.51 (95% CI: 0.30, 0.85) and 0.61 (95% CI: 0.32, 1.16), respectively. The median PFS and OS for the trastuzumab emtansine group were 10.8 months and not reached, respectively, compared with 5.7 months and 27.9 months, respectively, for the lapatinib plus capecitabine group.
Figure 1 Kaplan-meier curve of IRC-assessed progression-free survival


Figure 2 Kaplan-meier curve of overall survival


In study TDM4370g/BO21977, consistent treatment benefit of trastuzumab emtansine was seen in the majority of pre-specified subgroups evaluated, supporting the robustness of the overall result. In the subgroup of patients with hormone receptor-negative disease (n=426), the hazard ratios for PFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03), respectively. In the subgroup of patients with hormone receptor-positive disease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58, 0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.
In the subgroup of patients with non-measurable disease (n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91 (95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively. In patients ≥ 65 years old (n=138 across both treatment arms) the hazard ratios for progression-free survival (PFS) and Overall Survival (OS) were 1.06 (95% CI: 0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively. In patients 65 to 74 years old (n=113), based on IRC assessments, the hazard ratios for PFS and OS were 0.88 (95% CI: 0.53, 1.45) and 0.74 (95% CI: 0.37, 1.47), respectively. For patients 75 years or above, based on IRC assessments, the hazard ratios for PFS and OS were 3.51 (95% CI: 1.22, 10.13) and 3.45 (95% CI: 0.94, 12.65), respectively. The subgroup of patients 75 years or above did not demonstrate a benefit for PFS or OS, but was too small (n=25) to draw any definitive conclusions.
TDM4450g
A randomised, multicentre, open-label phase II study evaluated the effects of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with HER2-positive MBC who had not received prior chemotherapy for metastatic disease. Patients were randomised to receive trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks (n = 67) or trastuzumab 8 mg/kg intravenous loading dose followed by 6 mg/kg intravenously every 3 weeks plus docetaxel 75-100 mg/m2 intravenously every 3 weeks (n = 70).
The primary endpoint was investigator assessed Progression-Free Survival (PFS). The median PFS was 9.2 months in the trastuzumab plus docetaxel arm and 14.2 months in the trastuzumab emtansine arm (hazard ratio, 0.59; p = 0.035), with a median follow-up of approximately 14 months in both arms. The objective response rate (ORR) was 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine. The median duration of response was not reached with trastuzumab emtansine vs. 9.5 months in the control arm.
TDM4374g
A Phase II, single-arm, open-label study evaluated the effects of trastuzumab emtansine in patients with HER2-positive incurable, LABC or MBC. All patients were previously treated with HER2-directed therapies (trastuzumab and lapatinib), and chemotherapy (anthracycline, taxane, and capecitabine) in the neoadjuvant, adjuvant, locally advanced, or metastatic setting. The median number of anti-cancer agents that patients had received in any setting was 8.5 (range, 5-19) and in the metastatic setting was 7.0 (range, 3-17), including all agents intended for the treatment of breast cancer.
Patients (n = 110) received 3.6 mg/kg of trastuzumab emtansine intravenously every 3 weeks until disease progression or unacceptable toxicity.
The key efficacy analyses were ORR based on independent radiologic review and duration of objective response. The ORR was 32.7% (95% CI: 24.1, 42.1), n = 36 responders, by both IRC and investigator review. The median duration of response by IRC was not reached (95% CI, 4.6 months to not estimable).
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with trastuzumab emtansine in all subsets of the paediatric population in breast cancer (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties
Absorption
Trastuzumab emtansine is administered intravenously. There have been no studies performed with other routes of administration.
Distribution
Patients in TDM4370g/BO21977 who received 3.6 mg/kg of trastuzumab emtansine intravenously every 3 weeks had a mean maximum serum concentration (Cmax) of trastuzumab emtansine of 83.4 (± 16.5) μg/mL. Based on population PK analysis, following intravenous administration, the central volume of distribution of trastuzumab emtansine was (3.13 L) and approximated that of plasma volume.
Biotransformation (trastuzumab emtansine and DM1)
Trastuzumab emtansine is expected to undergo deconjugation and catabolism by means of proteolysis in cellular lysosomes.
In vitro metabolism studies in human liver microsomes suggest that DM1, a small molecule component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and to a lesser extent by CYP3A5. DM1 did not inhibit major CYP450 enzymes in vitro. In human plasma, trastuzumab emtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels. In vitro, DM1 was a substrate of P-glycoprotein (P-gp).
Elimination
Based on population pharmacokinetic (PK) analysis, following intravenous administration of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer, the clearance of trastuzumab emtansine was 0.68 L/day and the elimination half-life (t1/2) was approximately 4 days. No accumulation of trastuzumab emtansine was observed after repeated dosing of intravenous infusion every 3 weeks.
Based on population PK analysis, body weight, albumin, sum of longest diameter of target lesions by Response Evaluation Criteria In Solid Tumors (RECIST), HER2 shed extracellular domain (ECD), baseline trastuzumab concentrations, and aspartate aminotransferase (AST) were identified as statistically significant covariates for trastuzumab emtansine PK parameters. However, the magnitude of effect of these covariates on trastuzumab emtansine exposure, suggests that these covariates are unlikely to have any clinically meaningful effect on trastuzumab emtansine exposure. In addition, exploratory analysis showed that the impact of covariates (i.e., renal function, race and age) on the pharmacokinetics of total trastuzumab and DM1 was limited and was not clinically relevant. In nonclinical studies, trastuzumab emtansine catabolites including DM1, Lys-MCC-DM1, and MCC-DM1 are mainly excreted in the bile with minimal elimination in urine.
Linearity/non-linearity
Trastuzumab emtansine when administered intravenously every 3 weeks exhibited linear PK across doses ranging from 2.4 to 4.8 mg/kg; patients who received doses less than or equal to 1.2 mg/kg had faster clearance.
Elderly patients
The population PK analysis showed that age did not affect the PK of trastuzumab emtansine. No significant difference was observed in the PK of trastuzumab emtansine among patients < 65 years (n = 577), patients between 65-75 years (n = 78) and patients > 75 years (n = 16).
Patients with renal impairment
No formal PK study has been conducted in patients with renal impairment. The population PK analysis showed that creatinine clearance does not affect the PK of trastuzumab emtansine. Pharmacokinetics of trastuzumab emtansine in patients with mild (creatinine clearance CLcr 60 to 89 mL/min, n = 254) or moderate (CLcr 30 to 59 mL/min, n = 53) renal impairment were similar to those in patients with normal renal function (CLcr ≥ 90 mL/min, n = 361). Pharmacokinetic data in patients with severe renal impairment (CLcr 15 to 29 mL/min) are limited (n = 1), therefore no dosage recommendations can be made.
Patients with hepatic impairment
No formal PK study has been conducted in patients with hepatic impairment.
Other special populations
The population PK analysis showed that race did not appear to influence the PK of trastuzumab emtansine. Because most of the patients in trastuzumab emtansine clinical studies were females, the effect of gender on the PK of trastuzumab emtansine was not formally evaluated.
5.3 Preclinical safety data
Animal toxicology and/or pharmacology
Administration of trastuzumab emtansine was well tolerated in rats and monkeys at doses up to 20 and 10 mg/kg, respectively, corresponding to 2040 μg DM1/m2 in both species, which is approximately equivalent to the clinical dose of trastuzumab emtansine in patients. In the GLP toxicity studies, with the exception of irreversible peripheral axonal toxicity (observed only in monkeys at ≥ 10 mg/kg) and reproductive organ toxicity (observed only in rats at 60 mg/kg), partially or completely reversible dose dependent toxicities were identified in both animal models. Principal toxicities included liver (liver enzyme elevations) at ≥ 20 mg/kg and ≥ 10 mg/kg, bone marrow (reduced platelet and white blood cell count)/hematologic at ≥ 20 mg/kg and ≥ 10 mg/kg, and lymphoid organs at ≥ 20 mg/kg and ≥ 3 mg/kg, in rat and monkey, respectively.
Mutagenicity
DM1 was aneugenic or clastogenic in an in vivo single-dose rat bone marrow micronucleus assay at exposures that were comparable to mean maximum concentrations of DM1 measured in humans administered trastuzumab emtansine. DM1 was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay.
Impairment of fertility and teratogenicity
Dedicated fertility studies have not been conducted with trastuzumab emtansine. However, based on results from general animal toxicity studies, adverse effects on fertility can be expected.
Dedicated embryo-foetal development studies have not been conducted in animals with trastuzumab emtansine. Developmental toxicity of trastuzumab has been identified in the clinical setting although it was not predicted in the non-clinical program. In addition, developmental toxicity of maytansine has been identified in non-clinical studies which suggests that DM1, the microtubule-inhibiting cytotoxic maytansinoid component of trastuzumab emtansine, will be similarly teratogenic and potentially embryotoxic.
6. Pharmaceutical particulars
6.1 List of excipients
Succinic acid
Sodium hydroxide
Sucrose
Polysorbate 20
6.2 Incompatibilities
This medicinal product must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.
Glucose (5%) solution should not be used for reconstitution or dilution since it causes aggregation of the protein.
6.3 Shelf life
3 years.
Shelf-life of the reconstituted solution
Chemical and physical in-use stability of the reconstituted solution has been demonstrated for up to 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the reconstituted vials can be stored for up to 24 hours at 2°C to 8°C, provided it was reconstituted under controlled and validated aseptic conditions, and must be discarded thereafter.
Shelf-life of the diluted solution
The reconstituted Kadcyla solution containing sodium chloride 9 mg/ml (0.9%) solution for infusion, or sodium chloride 4.5 mg/ml (0.45%) solution for infusion, is stable for up to 24 hours at 2°C to 8°C, provided it was prepared under controlled and validated aseptic conditions. Particulates may be observed on storage if diluted in 0.9% sodium chloride (see section 6.6).
6.4 Special precautions for storage
Store in a refrigerator (2°C – 8°C).
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
Kadcyla is provided in 15 ml (100 mg) or 20 ml (160 mg) Type 1 glass vial closed with a grey-butyl rubber stopper coated with fluoro-resin laminate, and sealed with an aluminium seal with a white or purple plastic flip-off cap.
Pack of 1 vial.
6.6 Special precautions for disposal and other handling
Appropriate aseptic technique should be used. Appropriate procedures for the preparation of chemotherapeutic medicinal products should be used.
The reconstituted Kadcyla solution should be diluted in polyvinyl chloride (PVC) or latex-free PVC-free polyolefin infusion bags.
The use of 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion.
In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).
Instructions for reconstitution
• 100 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 5 mL of sterile water for injection into the vial.
• 160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8 mL of sterile water for injection into the vial.
• Swirl the vial gently until completely dissolved. Do not shake.
Reconstituted solution should be inspected visually for particulate matter and discolouration prior to administration. The reconstituted solution should be free of visible particulates, clear to slightly opalescent. The colour of the reconstituted solution should be colourless to pale brown. Do not use if the reconstituted solution contains visible particulates, or is cloudy or discoloured.
Instructions for dilution
Determine the volume of the reconstituted solution required based on a dose of 3.6 mg trastuzumab emtansine/kg body weight (see section 4.2):


The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250 mL of sodium chloride 4.5 mg/ml (0.45%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion. Glucose (5%) solution should not be used (see section 6.2). Sodium chloride 4.5 mg/ml (0.45%) solution for infusion may be used without a polyethersulfone (PES) 0.22-μm in-line filter. If sodium chloride 9 mg/ml (0.9%) solution for infusion is used for infusion, a 0.22 micron in-line polyethersulfone (PES) filter is required. Once the infusion is prepared it should be administered immediately. Do not freeze or shake the infusion during storage.
Disposal
The reconstituted product contains no preservative and is intended for single use only. Discard any unused portion.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
8. Marketing authorisation number(s)
EU/1/13/885/001
EU/1/13/885/002
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 15 November 2013
10. Date of revision of the text
23 October 2014
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
完整处方资料附件:http://www.info.pmda.go.jp/go/pack/4291426D1026_1_01/4291426D1026_1_01?view=body
--------------------------------------------
产地国家: 美国
原产地英文商品名:
KADCYLA 100MG/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
贺癌宁注射液 100毫克/支
中文参考药品译名:
曲妥珠单抗
生产厂家中文参考译名:
基因泰克公司
生产厂家英文名:
GENENTECH

-----------------------------------------------
产地国家: 美国
原产地英文商品名:
KADCYLA 160MG/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
贺癌宁注射液 160毫克/支
中文参考药品译名:
曲妥珠单抗
生产厂家中文参考译名:
基因泰克公司
生产厂家英文名:
GENENTECH
-----------------------------------------------
产地国家: 德国
原产地英文商品名:
KADCYLA 100MG/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
KADCYLA注射液 100毫克/支
中文参考药品译名:
曲妥珠单抗
生产厂家中文参考译名:
基因泰克公司
生产厂家英文名:
GENENTECH
-----------------------------------------------
产地国家: 德国
原产地英文商品名:
KADCYLA 160MG/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
KADCYLA注射液 160毫克/支
中文参考药品译名:
曲妥珠单抗
生产厂家中文参考译名:
基因泰克公司
生产厂家英文名:
GENENTECH
-----------------------------------------------
产地国家: 日本
原产地英文商品名:
KADCYLA  inj 100MG/5mL/vial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
KADCYLA注射液 100毫克/5毫升/支
中文参考药品译名:
曲妥珠单抗
生产厂家英文名:
Chugai Pharmaceutical Co., Ltd.
生产厂家中文参考译名:
中外制药

-----------------------------------------------
产地国家: 日本
原产地英文商品名:
KADCYLA  inj 160MG/8mLvial
原产地英文药品名:
ADO﹣TRASTUZUMAB EMTANSINE
中文参考商品译名:
KADCYLA注射液 160毫克/8毫升/支
中文参考药品译名:
曲妥珠单抗
生产厂家英文名:
Chugai Pharmaceutical Co., Ltd.
生产厂家中文参考译名:
中外制药

责任编辑:admin


相关文章
赫赛汀生物仿制药Herzuma(trastuzumab)获韩国批准
KADCYLA inj(Trastuzumab Emtansine[Genetical Recombination])
HERCEPTIN(Trastuzumab(Genetical Recombination))
HERCEPTIN(TRASTUZUMAB)注射用曲妥珠单抗
Herceptin SC(曲妥珠单抗+透明质酸,赫赛汀皮下缓释注射剂)
Kadcyla可有效用于晚期HER2阳性乳腺癌治疗
Kadcyla(Ado-trastuzumab Emtansine Injection for IV Use)
KADCYLA (trastuzumab emtansine) injection
Kadcyla(ado-trastuzumab emtansine)
Kadcyla(ado-trastuzumab emtansine)-曲妥珠单抗注射液
 

最新文章

更多

· Imbruvica(ibrutinib c...
· G-LASTA Subcutaneous I...
· Venetoclax(Venclexta)T...
· 曲美替尼片|MEKINIST(tr...
· CYRAMZA(ramucirumab in...
· 西罗莫司片|Rapalimus(...
· Lonsurf tablet(triflu...
· 色瑞替尼胶囊|Zykadia(...
· Tagrisso(osimertinib ...
· CYRAMZA Inf Konz(Ramu...

推荐文章

更多

· Imbruvica(ibrutinib c...
· G-LASTA Subcutaneous I...
· Venetoclax(Venclexta)T...
· 曲美替尼片|MEKINIST(tr...
· CYRAMZA(ramucirumab in...
· 西罗莫司片|Rapalimus(...
· Lonsurf tablet(triflu...
· 色瑞替尼胶囊|Zykadia(...
· Tagrisso(osimertinib ...
· CYRAMZA Inf Konz(Ramu...

热点文章

更多

· Imbruvica(ibrutinib c...